Physician profile
John Marino
NPI 1831105899
$69,508.82
in general payments reported to CMS, 2019-2025
34 companies · $3,114 in 2025
The $3,114 reported for 2025 was more than what 96% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,224 · 2020: $11K · 2021: $13K · 2022: $11K · 2023: $17K · 2024: $7,423 · 2025: $3,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $9,482 · Travel and Lodging: $337 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,827.50 |
| Food and Beverage | $9,481.96 |
| Travel and Lodging | $337.31 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29,357.47 | 2021-2025 | |
| Allergan, INC. | $13,485.72 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $5,510.24 | 2022-2025 | Quviviq, Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,219.15 | 2020-2025 | Caplyta |
| Alkermes, INC. | $2,417.10 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $2,396.13 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $2,223.70 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,811.36 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $1,626.05 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $1,363.99 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $1,024.44 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $982.40 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $732.99 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $696.65 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Glaxosmithkline, LLC. | $500.50 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $427.39 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $390.04 | 2021-2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $329.67 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $175.03 | 2020-2022 | |
| Bausch Health US, LLC | $163.94 | 2020-2023 | Aplenzin |
| Neuronetics, INC. | $129.79 | 2019-2020 | |
| Corium, LLC | $118.90 | 2022-2025 | Azstarys |
| Shire North American Group INC | $87.41 | 2019 | |
| Eisai INC. | $66.75 | 2020 | |
| Merck Sharp & Dohme LLC | $45.05 | 2022 | |
| Indivior INC. | $44.00 | 2019 | |
| Noven Therapeutics, LLC | $39.62 | 2024 | Xelstrym, Secuado |
| Beta Bionics, INC. | $30.33 | 2024 | Ilet Bionic Pancreas |
| Abbott Laboratories | $21.94 | 2019 | |
| Luye Pharma (USA) LTD. | $20.14 | 2025 | Erzofri Extended-Release |
| Alfasigma USA, INC. | $19.94 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.75 | 2023 | Xifaxan |
| Tris Pharma INC | $16.76 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Marino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.